Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trigriluzole with Nivolumab or Pembrolizumab in Advanced Malignancies
NCT03229278Phase 1Completed
- Sponsor
- Rutgers University
- Start
- Oct 2017
- Primary completion
- Oct 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of troriluzole in solid tumor, lymphoma, melanoma and 5 more, sponsored by Rutgers University. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Oct 2017; status: completed.
02
Drugs
troriluzole
03
Conditions
solid tumorlymphomamelanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03229278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229278.